EPS for Exelixis, Inc. (EXEL) Expected At $0.19

October 14, 2018 - By Ash

Exelixis, Inc. (NASDAQ:EXEL) LogoInvestors sentiment increased to 1.28 in 2018 Q2. Its up 0.12, from 1.16 in 2018Q1. It is positive, as 41 investors sold Exelixis, Inc. shares while 68 reduced holdings. 55 funds opened positions while 85 raised stakes. 234.21 million shares or 3.66% more from 225.93 million shares in 2018Q1 were reported.
Ls Advsrs Lc reported 0.02% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Rathbone Brothers Plc invested in 0.01% or 16,500 shares. Avalon Limited Co has invested 0.06% in Exelixis, Inc. (NASDAQ:EXEL). Winslow Evans & Crocker Inc holds 1,626 shares or 0.01% of its portfolio. Franklin Resource Inc accumulated 0.02% or 2.21M shares. Legal And General Gru Pcl accumulated 309,695 shares. Louisiana State Employees Retirement Sys has invested 0.07% in Exelixis, Inc. (NASDAQ:EXEL). Royal Commercial Bank Of Canada, a Ontario – Canada-based fund reported 413,447 shares. Cibc Asset, a Ontario – Canada-based fund reported 10,572 shares. Gradient Investments Lc reported 400 shares. State Common Retirement Fund reported 0.02% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). 4,414 are owned by Northwestern Mutual Wealth Mngmt. Prelude Capital Mgmt Llc reported 0% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Ameritas Inv Partners has 0.08% invested in Exelixis, Inc. (NASDAQ:EXEL). First Personal Financial Serv accumulated 250 shares.

Since April 11, 2018, it had 0 insider purchases, and 18 selling transactions for $14.98 million activity. FELDBAUM CARL B sold $705,797 worth of stock or 34,262 shares. $1.07M worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by WILLSEY LANCE on Tuesday, May 22. Hessekiel Jeffrey sold $447,200 worth of stock. The insider Schwab Gisela sold 22,500 shares worth $468,000. Shares for $303,750 were sold by Garber Alan M on Monday, April 16. MARCHESI VINCENT T also sold $285,450 worth of Exelixis, Inc. (NASDAQ:EXEL) on Friday, May 11.

Analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report $0.19 EPS on November, 7.They anticipate $0.07 EPS change or 26.92 % from last quarter’s $0.26 EPS. EXEL’s profit would be $56.63 million giving it 21.37 P/E if the $0.19 EPS is correct. After having $0.28 EPS previously, Exelixis, Inc.’s analysts see -32.14 % EPS growth. The stock increased 1.88% or $0.3 during the last trading session, reaching $16.24. About 2.51 million shares traded. Exelixis, Inc. (NASDAQ:EXEL) has declined 38.03% since October 14, 2017 and is downtrending. It has underperformed by 53.65% the S&P500.

Exelixis, Inc. (NASDAQ:EXEL) Ratings Coverage

Among 3 analysts covering Exelixis (NASDAQ:EXEL), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Exelixis had 4 analyst reports since May 3, 2018 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Wednesday, August 1 with “Hold”. Stifel Nicolaus maintained Exelixis, Inc. (NASDAQ:EXEL) rating on Thursday, May 3. Stifel Nicolaus has “Hold” rating and $29 target.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $4.84 billion. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 15.75 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

Another recent and important Exelixis, Inc. (NASDAQ:EXEL) news was published by Seekingalpha.com which published an article titled: “Exelixis: An Updated View” on September 14, 2018.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News